Legend Biotech Corp 6-K, filed Feb 2, 2022
Legend Biotech Corp (LEGN)
6-K
2022-02-02
For: 2022-02-02
View Original
Added on
April 07, 2026
About this 6-K
Legend Biotech Corp filed this 6-K on February 2, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Date of Report: February 2, 2022
Commission File Number: 001-39307
Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)
2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This report on Form 6-K shall be deemed to be incorporated by reference in the registration statements of Legend Biotech Corporation on Form F-3 (Nos.
333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.
Termination of Collaborative Research and License Agreement with Noile-Immune Biotech, Inc.
Legend Biotech USA, Inc. (“Legend Biotech”) and Noile-Immune Biotech, Inc. (“Noile”) have mutually agreed to terminate their Collaborative Research and
License Agreement dated as of April 27, 2020 (as amended, the “Agreement”), effective on January 28, 2022. Legend Biotech and Noile agreed to terminate the Agreement after the parties were not able to mutually agree upon an antigen target to be
selected for further research.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
LEGEND BIOTECH CORPORATION
(Registrant)
|
|||
|
February 1, 2022
|
By:
|
/s/ Ying Huang
|
|
|
Ying Huang, Ph.D.
|
|||
|
Chief Executive Officer and Chief Financial Officer
|
|||